Department of Health and Human Services March 16, 2017 – Federal Register Recent Federal Regulation Documents

National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meetings
Document Number: 2017-05285
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services
National Institute on Aging; Notice of Closed Meeting
Document Number: 2017-05284
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Document Number: 2017-05283
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
Center For Scientific Review; Notice of Closed Meetings
Document Number: 2017-05282
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Document Number: 2017-05281
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed Meetings
Document Number: 2017-05280
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed Meeting
Document Number: 2017-05279
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
Proposed Data Collection Submitted for Public Comment and Recommendations
Document Number: 2017-05265
Type: Notice
Date: 2017-03-16
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The Centers for Disease Control and Prevention (CDC), as part of its continuing efforts to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995. This notice invites comment on the proposed information collection project titled ``Anthropometric Information on Law Enforcement Officers.'' The purpose of this three-year data collection project is to assemble a database of body dimensions of 1,000 law enforcement officers to improve the design of police cruiser cabins and personal protective equipment (PPE).
Community Based Model of PHN Case Management Services (Behavioral Health)
Document Number: 2017-05248
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, Indian Health Service
Public Meeting on Patient-Focused Drug Development for Sarcopenia; Request for Comments; Correction
Document Number: 2017-05247
Type: Notice
Date: 2017-03-16
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration is correcting a notice entitled ``Public Meeting on Patient-Focused Drug Development for Sarcopenia'' that appeared in the Federal Register of December 14, 2016 (81 FR 90361). The document announced a public meeting and an opportunity for public comment on Patient-Focused Drug Development for Sarcopenia. The location of the meeting has changed and this document provides the updated meeting location.
Determination that CYANOCOBALAMIN INJECTION, 1 Milligram per Milliliter in a 10 Milliliter Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Document Number: 2017-05246
Type: Notice
Date: 2017-03-16
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) has determined that CYANOCOBALAMIN INJECTION, 1 milligram per milliliter in a 10 milliliter vial, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Product-Specific Guidances for Rifaximin; Revised Draft Guidance for Industry; Availability
Document Number: 2017-05245
Type: Notice
Date: 2017-03-16
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a revised draft guidance for industry on generic rifaximin oral tablets entitled ``Draft Guidance on Rifaximin.'' The revised draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for rifaximin oral tablets.
Office of The Director, National Institutes of Health; Notice of Meeting
Document Number: 2017-05195
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2017-05194
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Document Number: 2017-05193
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Document Number: 2017-05192
Type: Notice
Date: 2017-03-16
Agency: Department of Health and Human Services, National Institutes of Health